EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel oncolytic vaccinia virus armed with interleukin-27 is a potential therapeutic agent for the treatment of murine pancreatic cancer

Yangyang Jia, Yanru Wang, Guanghao Zhao, Yong Yang, Wenyi Yan, Ruimin Wang, Bing Han, Lihong Wang, Zhe Zhang, Lijuan Chen, Nicholas R Lemoine, Louisa S Chard Dunmall und 2 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Yangyang Jia und 13 weiteren Autor:innen. Beteiligte Einrichtung: Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Met…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Vaccinia virus, Oncolytic Virotherapy, Oncolytic Viruses. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, National Key Research and Development Program of China, Joint Fund for Science and Technology Research and Development of Henan province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic cancer has a complex immunosuppressive tumor microenvironment (TME), which is highly resistant to conventional therapies and emerging cancer immunotherapies. Oncolytic viruses are multifaceted killers of malignant tumors, which can selectively infect, replicate in and lyse tumor cells, release tumor-associated antigens to stimulate specific antitumor immune responses, and recruit immune cells into the TME, turning “cold” tumors “hot”. Here, we report a novel vaccinia virus (VV), VVLΔTKΔN1LΔA41L (with deletion of thymidine kinase (TK), N1L, and A41L genes) armed with interleukin 27 (IL-27), that can cure established tumors and promote long-term antitumor immunity in murine pancreatic cancer tumor models.

Methods

A novel oncolytic VV with deletion of the TK, N1L, and A41L genes, and expression of the red fluorescent protein (RFP) gene (VVL-TD-RFP) was constructed using CRISPR-Cas9-based homologous recombination. This virus was armed with IL-27, creating VVL-TD-IL-27. The characteristics of these viruses were evaluated in vitro using viral replication assays, cytotoxicity assays and ELISA. The antitumor effects of VVL-TD-IL-27 were evaluated using a variety of pancreatic cancer tumor models in vivo , and the mechanisms of antitumor effects were explored using flow cytometry, immunohistochemistry, ELISA and quantitative PCR.

Results

VVL-TD-RFP cured 71.4% of tumor-bearing mice, compared with 14.3% of animals treated with VVLΔTKΔN1L that does not have an A41L gene deletion. Efficacy was mainly dependent on elevated dendritic cell (DC) populations, activation of DC, CD86 + DC, and CD8 + effector memory T cells in the TME. Efficacy was further enhanced by arming VVL-TD-RFP with IL-27, which resulted in a cure rate of 100% and promoted long-term antitumor immunity. VVL-TD-IL-27 treatment increased the proportion of CD8 + TEM and decreased the proportion of regulatory T cells and macrophages in tumor tissues. It also polarized macrophages to an M1 phenotype in vivo . Furthermore, IL-27 exhibits strong anti-angiogenic effects.

Conclusions

VVL-TD-mIL-27 is a potential immunotherapy agent for the treatment of pancreatic cancer, and a clinical study of this virus is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsVaccinia virusOncolytic VirotherapyOncolytic VirusesInterleukin-27InterleukinsAnimalsMiceHumansTumor MicroenvironmentCell Line, TumorFemaleDisease Models, Animal

Stichwörter der Autor:innen

CytokineGastrointestinal CancerImmunotherapyOncolytic virus

Substanzen

Interleukin-27Interleukins

Autor:innen und Institutionen

  • Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Metabolic Dysregulation & the Prevention and Treatment of Esophageal Canc…
  • Department of Oncology, Air Force Medical Center, PLA, Beijing, China.
  • Department of Gastroenterology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Oncology, Henan International Joint Laboratory of Lung Cancer Biology and Therapeutics, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Centre for Cancer Biomarkers & Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK.

Förderung

  • Medical Research Council
  • National Key Research and Development Program of China
  • Joint Fund for Science and Technology Research and Development of Henan province
  • National Natural Science Foundation of China

Zitieren

APA

Jia, Y., Wang, Y., Zhao, G., Yang, Y., Yan, W., Wang, R., Han, B., Wang, L., Zhang, Z., Chen, L., Lemoine, N. R., Chard Dunmall, L. S., Wang, P., & Wang, Y. (2025). Novel oncolytic vaccinia virus armed with interleukin-27 is a potential therapeutic agent for the treatment of murine pancreatic cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010341

Vancouver

Jia Y, Wang Y, Zhao G, Yang Y, Yan W, Wang R, et al. Novel oncolytic vaccinia virus armed with interleukin-27 is a potential therapeutic agent for the treatment of murine pancreatic cancer. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010341

BibTeX
@article{Jia2025,
  author = {Jia, Yangyang and Wang, Yanru and Zhao, Guanghao and Yang, Yong and Yan, Wenyi and Wang, Ruimin and Han, Bing and Wang, Lihong and Zhang, Zhe and Chen, Lijuan and Lemoine, Nicholas R and Chard Dunmall, Louisa S and Wang, Pengju and Wang, Yaohe},
  title = {Novel oncolytic vaccinia virus armed with interleukin-27 is a potential therapeutic agent for the treatment of murine pancreatic cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010341}
}
Kostenlos starten →